Related Experiment Videos
Presentation of tumor antigens
D N Hart1, J L Schultze, A K Stewart
1Mater Medical Research Institute, Brisbane, Queensland, Australia.
Seminars in Hematology
|February 16, 1999
Summary
Dendritic cells are key for immunotherapy against multiple myeloma. Strategies focus on enhancing dendritic cell function and using tumor cells to present antigens, with early trials showing promise but also inflammation.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Dendritic cells (DCs) are crucial for initiating T-lymphocyte responses, making them vital for multiple myeloma immunotherapies.
- Tumor environments can inhibit DC maturation and activation, hindering anti-tumor immunity.
- Tumor-associated antigens (TAAs) are recognized by lymphocytes, but immune evasion strategies exist.
Purpose of the Study:
- To explore the role of dendritic cells in multiple myeloma immunotherapy.
- To investigate strategies for overcoming tumor-induced immune suppression.
- To evaluate novel therapeutic approaches using modified tumor cells and adenoviral vectors.
Main Methods:
- Investigating ex vivo pulsing of dendritic cells with antigens for reinfusion.
- Studying tumor cells as a source of antigens for T-cell presentation.
- Conducting Phase I trials of immunotherapy using adenovirus-infected autologous plasma cells.
Main Results:
- Adenoviral vectors carrying therapeutic genes (IL-2, IL-12, B7-1) were successfully detected in tumor cells post-injection.
- Interleukin-2 (IL-2) expression was confirmed within 7 days.
- Inflammation was noted as the primary side effect.
Conclusions:
- Dendritic cell-based strategies hold potential for multiple myeloma immunotherapy.
- Further research is needed to optimize DC function and antigen presentation.
- Adenoviral vector-mediated gene delivery shows early therapeutic potential but requires careful monitoring for side effects.